AustCancer attracts $2m investment
Friday, 08 October, 2004
US biotech company Bioaccelerate will invest AUD$1.88 million into Australian Cancer Technologies (AustCancer, ASX:ACU) through a private share placement of 4,893,301 ACU shares at $0.384 per share.
The investment comes with a commitment for a wider collaboration between the two companies, focusing on a new prostate cancer compound introduced by Bioaccelerate, and work on a pancreatic cancer drug recently acquired by AustCancer from German company RESprotect.
Bioaccelerate's prostate cancer project is based on two proteins -- calreticulin (EAF1) and TID1 -- which are downregulated in prostate cancer. Potential lead compounds, which modulate the expression or effectiveness of these two proteins, are being developed, with the aim of commencing Phase I clinical trials in 2005.
The placement is expected to be ratified at the company's AGM on November 4, 2004.
AustCancer is also planning to offer shareholders a non-renounceable rights issue one new share for every ten shares they hold as at October 18, 2004 at an issue price of $0.35 per share -- a 14.7 per cent discount to the one month volume weighted average price. The issue is expected to raise up to $4 million.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
